Results 211 to 220 of about 9,263,948 (394)
Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK) [PDF]
Introduction: We report a cost-effectiveness evaluation of granulocyte colony-stimulating factors (G-CSFs) for prevention of febrile neutropenia (FN) following chemotherapy for non-Hodgkin’s lymphoma (NHL) in the United Kingdom (UK).
Akehurst, R+3 more
core
A phase II, single‐arm, multicentre trial was conducted by Fondazione Italiana Linfomi (FIL) to investigate the combination of copanlisib plus rituximab and bendamustine (copa‐BR) in transplant‐ and chimeric antigen receptor (CAR)‐T‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Thirty‐seven patients were enrolled.
Mattia Novo+24 more
wiley +1 more source
Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: A progress report [PDF]
Tenali Gnana Sagar+2 more
openalex +1 more source
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia+11 more
wiley +1 more source
Treatment of patients with advanced or bulky Hodgkin disease with a 12‐week doxorubicin, bleomycin, vinblastine, and dacarbazine‐like chemotherapy regimen followed by extended‐field, full‐dose radiotherapy [PDF]
Malika Djeridane+17 more
openalex +1 more source
We applied three major comorbidity scoring systems—CIRS, HCT‐CI, and Severe4—to a cohort of 379 patients with LBCL treated with CAR‐T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used. However, a high comorbidity burden did not negatively impact the tolerability of CAR‐T treatment, including the ...
Eugenio Galli+13 more
wiley +1 more source
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu+17 more
wiley +1 more source
Outcome and Challenges in the Treatment of Pediatric Hodgkin Lymphoma With Euronet-PHL-C1 Protocol: Experience From a Resource-Limited Country. [PDF]
Bechara E+8 more
europepmc +1 more source
Summary Peripheral T‐cell lymphoma (PTCL) is relatively prevalent in Asian populations. Previous studies suggest that germline mutations in familial haemophagocytic lymphohistiocytosis (FHL)‐related genes may predispose individuals to lymphoproliferative disorders.
Chong Wei+4 more
wiley +1 more source